Robotics could optimize subretinal delivery of gene therapies

Injection in the subretinal space, currently performed or investigated for several cell-based and gene therapy procedures, could soon become more precise and safer with the help of robotics.
“Robotics can offer precision, accuracy and that degree of steadiness that is key for successful subretinal delivery,” Marc de Smet, MD, PhD, said at the virtual Euretina congress.
Gene therapy is advancing quickly, and one option, Luxturna (voretigene neparvovec, Novartis), is on the market at the price of US$425,000 per injection. Subretinal delivery is a delicate procedure that requires exact

Full Story →